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Increasing evidence suggests that the misfolding and ag-
gregation of different disease-associated proteins such
as amyloid-β (Aβ) and tau in Alzheimer’s disease (AD),
α-synuclein in Parkinson’s Disease (PD) and dementia
with Lewy bodies (DLB), or prion protein (PrP) in prion
diseases is based on a common molecular mechanism of
nucleation-dependent protein polymerization [1-3]. Con-
sistent with this concept it has been recently demon-
strated that the aggregation and deposition of Aβ, tau, and
α-synuclein in the brain can be stimulated in animal
models by injection of inocula that contain aggregated
forms of these proteins (for a review see: [4]). Additionally,
intracerebral implantation of stainless steel wires previ-
ously contaminated with Aβ-containing brain extract
was found to stimulate cerebral beta-amyloidosis in
APP23 transgenic mice [5], and Aβ aggregates resisted in-
activation of nucleating (“seeding”) activity by boiling [5]
or formaldehyde [6]. Taken together, these findings raised
concerns that the transmission of pathological protein
particles from common neurodegenerative diseases may
possibly pose a risk to patient safety, e.g. in transfusion
medicine or surgery. However, so far neither experimental
nor epidemiological studies provided evidence for a trans-
mission of severe or even fatal disease by Aβ-, tau- or α-
synuclein aggregates [4]. Yet, stimulation of cerebral
protein aggregation by iatrogenically transmitted Aβ-,
tau- or α-synuclein particles could possibly have harmful
effects below full-blown disease transmission. For α-
synuclein such scenarios have been experimentally exem-
plified. Intracerebrally or intramuscularly injected samples* Correspondence: BeekesM@rki.de
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unless otherwise stated.containing aggregated human α-synuclein led to both
earlier onset of severe motor dysfunction in and prema-
ture death of transgenic mice expressing mutated human
α-synuclein [7-9]. In addition, intracerebral injection of
similar inocula caused neurotoxic effects and neurological
impairments in transmission experiments with wild-type
mice [10]. Whether those harmful effects can be also
caused by transmitted protein particles in humans who
express mutated or normal α-synuclein, Aβ or tau is still
unknown.Testing the depletion of aggregated amyloid-β,
tau and α-synuclein in carrier assays
Thus, the ability to decontaminate medical instruments
from aggregated Aβ, tau and α-synuclein may potentially
add to patient safety. When discussing this question,
data on the efficacy of routinely applicable reprocessing
procedures for medical instruments against Aβ-, tau-
and α-synuclein aggregates can provide helpful guidance.
For this reason, we assessed the activity of different
reprocessing procedures against those contaminations in
depletion assays that used stainless steel wire grids as
surrogates for medical instruments. These assays were de-
veloped by adapting a method previously used to test the
decontamination of medical devices from contaminations
of infectious prion protein (for details see [11]). In brief:
Two stainless steel wire grids (100 × 5 mm; DIN 1.4301,
Spörl) each were contaminated with 20% (w/v) brain tis-
sue homogenates from patients with AD or demential
α-synuclein aggregation disease (SD) and jointly used
for the analysis of the respective decontamination treat-
ment. Grids were air-dried for 2 days at room temperature
(RT) and subsequently incubated in the formulations for
the time-periods and at the temperatures indicated in
Figure 1. After incubation in the specified formula-
tions, some grids were additionally steam sterilized at
134°C for the indicated time periods. Residual proteinal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 (See legend on next page.)
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Figure 1 In vitro carrier assay for testing the depletion of aggregated human α-synuclein, amyloid-β and tau. Western blot detection of
aggregated human α-synuclein (a), Aβ (b), and tau (c) by the indicated antibodies (Table 1) in protein eluates from steel wire grids that had been
contaminated with 20% (w/v) brain tissue homogenates (BTH) from donors with SD (a) or AD (b and c). Lanes “SD” (a), “AD” (b and c) and “N” (a-c)
(“SD*” [a], “AD*” [b and c] and “N*” [a-c]) represent 5 μl (or 20 μl in lanes marked with an asterisk) 20% (w/v) BTH from SD- and AD patients and
control donors (without SD or AD), respectively. The identity of α-synuclein, Aβ, and tau aggregates in BTH and on steel wire grids washed with
bi-distilled water was confirmed by two different antibodies each (most right lanes in a-c represent steel wire grids that had been contaminated with
BTH from control donors). For testing the presence and depletion of aggregated α-synuclein, Aβ, and tau contaminated wires were processed by I)
washing with bi-distilled water (a-c, lanes “A. bidest.”), or exposure to II) 0.25% (v/v) peracetic acid for 1 hour at room temperature (RT) (a-c, lanes “PAA-
1 h-RT”), III) a mixture of 0.2% (w/v) SDS and 0.3% (w/v) NaOH (pH 12.7 - 12.9, non-adjusted) for 10 min. at RT (a-c, lanes “SDS/NaOH-10'-RT”), IV) an alkaline
cleaner (0.5%, pH 11.6 - 12.0 [non-adjusted]) [13] for 10 min. at 55°C (a-c, lanes “Alkaline cleaner-10'-55°C”), V) 1 M NaOH (pH 13.5 - 13.8, non-adjusted)
for 1 h at RT (a-c, lanes “NaOH-1 h-RT”), VI) a solution of 7.5% (w/v) H2O2 containing Cu
2+ ions [14] (prepared in 100 mM NaCO3 [pH 9.5, adjusted] by
adding CuCl2 to a final concentration of 500 μM) for 15 min. at RT (a-c, lanes “ H2O2/CuCl2-15′-RT”), VII) treatment as in III) with subsequent
PVSS for 5 min. at 134°C (b and c, lanes “SDS/NaOH-10′-RT + 5′-134°C”), VIII) treatment as in IV) with subsequent PVSS for 5 min. (b and c, lanes
“Alkaline cleaner-10′-55°C + 5′-134°C”) or 18 min. (b and c, lanes “Alkaline cleaner-10′-55°C + 18′-134°C”), or IX) treatment as in VI) with subsequent PVSS
for 5 min. (b and c, lanes “H2O2/CuCl2-15′- RT + 5′-134°C”). PVSS was always performed at 3 bar. ab: antibody. Vertical brackets indicate insoluble
α-synuclein-, Aβ- and tau aggregates retained in stacking gels.
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wire grids by boiling in 300 μl double-concentrated elec-
trophoresis loading buffer and analysed by Western blot-
ting. 12% Tris-Glycine gels were used for sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis (SDS-
PAGE), and after SDS-PAGE the whole gels (including the
stacking gels) were blotted onto polyvinylidene difluoride
membranes. The blots were incubated in the antibody-
and blocking solutions specified in Table 1, and labelled
proteins were visualized using CDP-star and Amersham
Hyperfilm ECL.
In our study we focused on large aggregates of patho-
logical Aβ, tau and α-synuclein. These aggregates were
largely retained in the stacking gel (indicated in Figure 1
by vertical brackets) and constituted the molecular spe-
cies which seemed to be most difficult to wash off from
the grids below the threshold of detection (Figure 1a-c,Table 1 Antibodies and blocking reagents for Western blot det
1st Antibody Provider and
product code
Epitope Dilutio
























6E10 (monoclonal) Covance, Emeryville,
USA SIG-39320
aa 3-8 of Aβ 1:2,000
4G8 (monoclonal) Covance, Emeryville,
USA SIG-39220
aa 17-24 of Aβ 1:1,000
aTina Zimmermann, personal communication and diploma thesis (2012, Establishme
diseases. Free University of Berlin, Berlin, Germany).lanes “A. bidest. [100 μl], [5 μl], [1 μl]”). Furthermore,
our rationale was based on the general assumption that
depletion of such protein aggregates from medical instru-
ments concomitantly reduces potentially harmful seeding
effects. Recent findings by Duran-Aniotz and colleagues
experimentally confirmed this rationale for Aβ aggregates
from human AD brain extracts [12].
Substantial depletion of amyloid-β-, tau- and
α-synuclein aggregates on test carriers by
exposure to cleaners and steam sterilization
When we assessed the activity of prion-effective reproces-
sing procedures against Aβ-, tau and α-synuclein aggregates
we found that these were simultaneously reduced up to
100-fold, and below the threshold of detection, by alkaline
formulations, applied at RT, such as 1 M NaOH (Figure 1a-c,
lanes “NaOH-1 h-RT”) or a mixture of 0.2% SDS and 0.3%ection of aggregated human α-synuclein, amyloid-β and tau
n Blocking solution 2nd Antibody Dilution
0.03% (w/v) Casein in
TBS with 0.05% (w/v)
Tween 20
Alkaline-phosphatase-conjugated
goat anti-mouse IgG (DAKO)
1:5,000
3% (w/v) Low-fat milk
powder in TBS with
0.05% (w/v) Tween 20
Alkaline-phosphatase-conjugated
goat anti-rabbit IgG (DAKO)
1:10,000
3% (w/v) Low-fat milk
powder in TBS with
0.05% (w/v) Tween 20
Alkaline-phosphatase-conjugated
goat anti-mouse IgG (DAKO)
1:10,000
0.03% (w/v) Casein in
TBS with 0.05% (w/v)
Tween 20
Alkaline-phosphatase-conjugated
goat anti-mouse IgG (DAKO)
1:10,000
5% (w/v) Low-fat choco
powder in TBS with
0.05% (w/v) Tween 20a
Alkaline-phosphatase-conjugated
goat anti-mouse IgG (DAKO)
1:10,000
5% (w/v) Low-fat choco
powder in TBS with
0.05% (w/v) Tween 20a
Alkaline-phosphatase-conjugated
goat anti-mouse IgG (DAKO)
1:10,000
nt of the organotypic slice culture assay as a model for neurodegenerative
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sterilization (PVSS), respectively, for 5 minutes at 134°C
(Figure 1a, lane “SDS/NaOH-10'-RT“ and Figure 1b and c,
lanes ”SDS/NaOH-10′-RT + 5′-134°C”).
The same depletion effects were observed for α-synuclein
aggregates after exposure to more material-friendly formu-
lations such as a commercially available alkaline cleaner
[13] for 10 minutes at 55°C (Figure 1a, lane “Alkaline
cleaner-10′-55°C”), or a 7.5% H2O2 solution containing
low concentrations of Cu2+ ions [14] for 15 minutes at RT
(Figure 1a, lane “H2O2/CuCl2-15′-RT”). Similarly effective
depletion of Aβ- and tau aggregates was achieved when
treatments with the H2O2/CuCl2 formulation or the alkaline
cleaner were followed by PVSS at 134°C for 5 or 18 minutes,
respectively (Figure 1b and c, lanes “H2O2/CuCl2-15′-RT +
5′-134°C” and “Alkaline cleaner-10′-55°C + 18′-134°C”).
These findings of our pilot study suggest that a simultan-
eous and quantifiably depletion of pathological Aβ-,
tau-and α-synuclein aggregates is basically feasible by
using prion-effective formulations in routine procedures
for the reprocessing of selected medical devices. Peracetic
acid (PAA), a commonly used disinfectant being not ef-
fective against prions, failed to achieve a detectable deple-
tion of aggregated Aβ, tau and α-synuclein in our assays
(Figure 1a-c, lanes “PAA-1 h-RT”).
How to deal with transmissible protein seeding in
the reprocessing of medical devices?
It is open to discussion whether the findings from trans-
mission studies in animals give reason to include specific
preventive measures against pathological amyloid-β-, tau-
and α-synuclein aggregates in the routine decontamination
of certain medical devices. At the same time, studies spe-
cifically pursuing the identification and validation of such
measures are still scarce. Therefore, available or newly de-
veloped assays should be used to experimentally assess on
a broader scale the efficacy of reprocessing procedures
for medical devices against AD-, PD- or DLB-associated
protein aggregates. Ideally, such assessments would also
include measurements of the reduction of seeding ac-
tivity in vitro and/or in vivo. Broadening the data
basis from both transmission and decontamination stud-
ies could greatly help to answer the question of how to
reprocess medical devices in view of transmissible protein
seeding.Abbreviations
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